| Project/Area Number |
17K11141
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
田岡 利宜也 香川大学, 医学部, 助教 (10403784)
筧 善行 香川大学, 大学本部, 学長 (20214273)
常森 寛行 香川大学, 医学部附属病院, 講師 (20380173)
加藤 琢磨 香川大学, 医学部, 助教 (70625673)
田島 基史 香川大学, 医学部附属病院, 助教 (60524064)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 前立腺癌 / 監視療法 / MRI / mpMRI |
|---|
| Outline of Final Research Achievements |
Comparison between MRI and pathological findings showed that there are significant cancers that clinically determine prognosis even in areas where no clear findings are found on MRI. In other words, performing active surveillance based solely on MRI is still dangerous at this time.
|
| Academic Significance and Societal Importance of the Research Achievements |
より安全性を担保した監視療法プログラムには、現時点では再生検が必要である。今後は遺伝子を含めた新規バイオマーカー、新規画像検査の発展が待たれる。
|
